Report
MaaT Pharma FIRST LOOK: Positive DSMB for MaaT033, the road goes on
The DSMB has positively reviewed the first safety data from MaaT033's Phase 2b PHOEBUS program and recommended continuation without modifications to the trial design. MaaT033 is an orally formulated, pooled microbiome therapy that is being tested to improve survival rates in patients undergoing allo-HSCT. We deem the company is well on track, and look forward to topline readout from its pivotal study for lead asset MaaT013 toward YE24. We reiterate our € 14 TP and Buy rating.
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.